__timestamp | Dr. Reddy's Laboratories Limited | Genmab A/S |
---|---|---|
Wednesday, January 1, 2014 | 38783000000 | 79529000 |
Thursday, January 1, 2015 | 42585000000 | 91224000 |
Friday, January 1, 2016 | 45702000000 | 102413000 |
Sunday, January 1, 2017 | 46372000000 | 146987000 |
Monday, January 1, 2018 | 46910000000 | 213695000 |
Tuesday, January 1, 2019 | 48890000000 | 342000000 |
Wednesday, January 1, 2020 | 50129000000 | 661000000 |
Friday, January 1, 2021 | 54559000000 | 1283000000 |
Saturday, January 1, 2022 | 62081000000 | 2676000000 |
Sunday, January 1, 2023 | 105931000000 | 3297000000 |
Monday, January 1, 2024 | 77201000000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent companies: Genmab A/S and Dr. Reddy's Laboratories Limited, from 2014 to 2023.
Dr. Reddy's Laboratories, a major player in the global pharmaceutical market, has seen its SG&A expenses grow by approximately 173% over the past decade, peaking in 2023. This reflects their aggressive expansion and marketing strategies. In contrast, Genmab A/S, a biotechnology company, has experienced a more modest increase in SG&A expenses, with a notable rise of over 400% from 2014 to 2023, indicating strategic investments in research and development.
While Dr. Reddy's expenses dwarf those of Genmab, the latter's rapid growth in SG&A spending highlights its commitment to innovation and market presence. The data for 2024 is incomplete, suggesting ongoing developments in both companies' financial strategies.
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Healthcare Companies
Number of Employees for Top 10 Pharma Companies
Average Market Capitalization of Abbvie Annually
5 Year Trend in Market Capitalization for AbbVie
5 Year Trend in Average Market Capitalization for AbbVie
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters